NucleofectorTM technology allows non-viral gene transfer directly into the nucleus of primary cells and cell lines, thereby providing rapid target gene validation, acceleration of drug development and new applications for gene therapy.
Amaxa Biosystems
Home - Lonza Cologne AG
2024-06-16
amaxa develops and commercializes non-viral transfection technologies and leverages them for academic, industrial and clinical applications. One of amaxa's key competencies is non-viral gene transfer directly into the nucleus of primary cells and cell lines in single well as well as 96-well format.